Evia Bio, Inc.
StreetZero Signal 76
About Evia Bio, Inc.
Evia Bio is a life science innovation company enabling the growing cell therapy market. The company provides DMSO-free cryopreservation products and solutions developed by world-leading cryobiologist Allison Hubel, PhD. It partners with cell therapy companies to advance products to clinical trials and commercialization using all-natural organic compounds to protect cell integrity during cryopreservation.
LATEST FUNDINGPrivate Placement
$5.5M
Announced 2026-09-28
IN THE NEWS
- 🔗 Evia Bio Company Overview, Contact Details & Competitors | LeadIQ
- 🔗 Evia Bio - Better and Safer Therapeutics Enabled by All-Natural Cryopreservation.
- 🔗 Evia Bio - 2026 Funding Rounds & List of Investors - Tracxn
- 🔗 Press Release: Evia Bio Closes Series A Financing to Accelerate Growth of DMSO-Free Cryopreservation Solutions - Evia Bio
- 🔗 Evia Bio | Cryopreservation Technology
EMPLOYEES2-10
FOUNDED—
HQMinneapolis, MN, United States
Industry
Biotechnology
Tags
BiotechnologyCryopreservationCell Therapy
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Provides non-DMSO cryopreservation solutions for cell therapies
- Led by Chairman and CEO Jeff Allen with technology from Allison Hubel, PhD
- Partners with cell therapy companies for clinical and commercial advancement
- Operates with estimated revenue range of $1M-$10M
Ask StreetZero about Evia Bio, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account